公开(公告)号：EP1565429B1

公开(公告)日：2009-05-13

申请号：EP03770917.7

申请日：2003-11-10

申请人： NeuroSearch A/S

发明人： VALGEIRSSON, Jon ,  NIELSEN, Elsebet Ostergaard, c/o Neurosearch A/S ,  PETERS, Dan, c/o Neurosearch A/S

IPC分类号： C07C275/42 ,  C07C309/46 ,  C07D209/40 ,  C07D213/72 ,  C07D231/56 ,  C07D257/04 ,  C07D271/07 ,  C07D333/36 ,  A61K31/17 ,  A61K31/19 ,  A61K31/381 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/44

CPC分类号： C07D213/75 ,  C07C275/42 ,  C07C309/51 ,  C07C2603/18 ,  C07D209/40 ,  C07D231/56 ,  C07D257/04 ,  C07D271/07 ,  C07D317/66 ,  C07D333/36

摘要： This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

摘要翻译： 本发明涉及可用作离子型GluR5受体的选择性和非竞争性拮抗剂的新型芳基脲基苯甲酸衍生物。 由于其生物活性，本发明的芳基脲基衍生物被认为可用于治疗对天冬氨酸或谷氨酸受体的调节有反应的疾病。 此外，本发明提供了根据本发明使用的化合物，以及包含化合物的药物组合物，以及治疗对天冬氨酸或谷氨酸受体的调节作用的疾病或病症或病症的方法。

公开(公告)号：EP1565429A2

公开(公告)日：2005-08-24

申请号：EP03770917.7

申请日：2003-11-10

申请人： NEUROSEARCH A/S

发明人： VALGEIRSSON, Jon ,  NIELSEN, Elsebet Ostergaard,c/o Neurosearch A/S ,  PETERS, Dan,c/o Neurosearch A/S

IPC分类号： C07C275/42 ,  C07C309/46 ,  C07D209/40 ,  C07D213/72 ,  C07D231/56 ,  C07D257/04 ,  C07D271/07 ,  C07D333/36 ,  A61K31/17 ,  A61K31/19 ,  A61K31/381 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/44

CPC分类号： C07D213/75 ,  C07C275/42 ,  C07C309/51 ,  C07C2603/18 ,  C07D209/40 ,  C07D231/56 ,  C07D257/04 ,  C07D271/07 ,  C07D317/66 ,  C07D333/36

摘要： This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.